Clinical Edge Journal Scan

SGLT2 inhibitors with metformin do not influence fracture risk


 

Key clinical point : Sodium-glucose transporter-2 inhibitors (SGLT2is) combined with metformin therapy did not influence fracture risk in patients with type 2 diabetes mellitus (T2DM).

Major finding : SGLT2is and metformin combination therapy did not increase the risk of fracture vs. metformin monotherapy or other comparators in patients with T2DM (odds ratio, 0.97; 95% confidence interval, 0.71-1.32).

Study details : A meta-analysis of 25 randomized controlled trials including 19,500 participants with T2DM.

Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.

Source: Qian BB et al. Osteoporos Int. 2020 Aug 11. doi: 10.1007/s00198-020-05590-y .

Recommended Reading

Osteoporosis: Cardiovascular safety of abaloparatide in postmenopausal women
MDedge Rheumatology
Psoriatic arthritis, psoriasis, and osteoporosis: What is the association?
MDedge Rheumatology
Glucocorticoid-induced osteoporosis: Teriparatide may be a good alternative to denosumab
MDedge Rheumatology
Osteoporosis: September 2020
MDedge Rheumatology
Denosumab safe and effective in chronic liver disease patients with osteoporosis
MDedge Rheumatology
Teriparatide can be considered in premenopausal women with idiopathic osteoporosis
MDedge Rheumatology
Metformin may attenuate osteoporosis risk in diabetic patients with carcinoma in situ
MDedge Rheumatology
Osteoporosis: Predictors of vertebral fracture risk in patients receiving denosumab
MDedge Rheumatology
Osteoporosis increases likelihood of revision surgery after long spinal fusion for adult spinal deformity
MDedge Rheumatology
Sepsis and osteoporosis: What’s the link?
MDedge Rheumatology